[1]Forman L.A note on the depigmentary properties of monobenzylether of hydroquinone.Br J Dermatol,1953,65(11):406-409[2]Zhu YP,Wang SQ, Xu A.A mouse model of vitiligo induced by monobenzone.Exp Dermatol,2013,22(7):499-501[3]Harris JE,Harris TH,Weninger W, et al.A Mouse Model of Vitiligo with Focused Epidermal Depigmen- tation Requires IFN-γ for Autoreactive CD8+T Cell Accumulation in the Skin.J Invest Dermatol,2012,10:1-8[4]Becker Jr SW and Spencer MC.Evaluation of monobenzone.J Am Med Assoc,1962,180(4):279-284[5]Catona A and Lanzer D.Monobenzone Superfade vitiligo and confetti-like depigmentation. Med J Aust,1987:146[6]Van den Boorn JG, Picavet DI and van Swieten PF,et al.Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy.J Invest Dermatol,2011,131(6):1240-1251[7]Van den Boorn JG, Konijnenberg D and Tjin EP et al.Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG.PLoS ONE,2010,5(5):e10626-[8]Van den Boorn JG, Melief CJ and Luiten RM.Monobenzone-induced depigmentation: from enzymatic blockade to autoimmunity.Pigment Cell Melanoma Res,2011,24(4):673-679[9]龙子江,白玫,樊彦等,化学脱色法制备白癜风动物模型.安徽中医学院学报,1997,16(6):60-61[10]McGuire J and Hendee J.Biochemical basis for depigmentation of skin by phenolic germicides.J Invest Dermatol,1971,57(4):256-261[11]Steitz J,Bruck J and Lenz J,et a1.Peripheral CD8+T cell tolerance against melanocytic self-antigens in the skin is regulated in two steps by CD4+T cells and local inflammation: implications for the pathophysiology of vitiligo.J Invest Dermatol,2005,124(1):144-150[12]van den Boorn JG, and Konijnenberg D,Dellemijn Trees AM,et al.Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients.J Investig Dermatol,2009,129(9):2220-2232[13]杜宇,陈德宇,杨西群等,白癜风患者血清和皮肤组织液IL-18及IFN-γ水平变化的研究.中国皮肤性病学杂志,2004,18(10):582-584[14]Lebre MC,van der Aar AM and van BL, et al.Human keratinocytes express functional Toll-like receptor 3,4,5and 9.J Invest Dermatol,2006,127(2):331-341 |